Duke University

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Duke University sits in the top decile of US sponsors by registered trial count (#9 of 15,742 sponsors by registered trial count).

1,725 total trials 187 currently recruiting 1244 completed early-phase tilt top decile by trial count

Duke University: 1,725 sponsored US clinical trials, 187 recruiting.

Duke University sponsors 1,725 registered US clinical trials on ClinicalTrials.gov, 187 of them currently recruiting, and 1,244 completed. 175 of these trials are in Phase 3-4 (later-stage) and 311 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 15 trials.

Top-decile sponsor footprint

Duke University ranks in the top decile of sponsors by registered trial count (#9 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 55/100

1,244 of 1,444 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,725 total, page 30 of 35

COMPLETED NA

Wheeled Mobility in Everyday Life

NCT00981344
TERMINATED Phase 2

Stereotactic Radiosurgery in Treating Patients With Brain Metastases

NCT00811655
COMPLETED NA

Study of Massage Therapy Within a Brain Tumor Setting

NCT00873184
COMPLETED

Development & Validation of Utilities for Health States Relevant to Cervical Cancer Patients

NCT00788216
COMPLETED Phase 3

Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study)

NCT00763867
COMPLETED

Transfusions and Nitric Oxide Level in Preterm Infants

NCT00787124
COMPLETED NA

En Pareja: A Latino Couples Intervention to Help Expectant Fathers Quit Smoking

NCT01040949
COMPLETED

Early Childhood Follow-up of Congenital Diaphragmatic Hernia Survivors

NCT01029665
COMPLETED Phase 1

PARTNER Recruitment and Brief Intervention Pilot Study

NCT00735956
TERMINATED Phase 2

Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC

NCT00787267
COMPLETED NA

Diet, Imaging and Energy Balance Trial (DIET)

NCT00787280
COMPLETED NA

Telemedicine vs. Face-to-Face Cancer Genetic Counseling

NCT00609505
COMPLETED NA

Coping Skills for Patients With Chronic Obstructive Pulmonary Disease (COPD) and Their Caregivers

NCT00736268
TERMINATED Phase 2

Stereotactic Radiosurgery After Surgery in Treating Patients With Brain Metastases

NCT00814463
COMPLETED

Memory and Picture Viewing Study

NCT00736203
COMPLETED Phase 1

Phase I/II Trial of Radiation, Avastin and Tarceva for Pancreatic Adenocarcinoma

NCT00735306
COMPLETED

Lymph Node Counts in Endometrial Cancer Staging

NCT02335775
TERMINATED Phase 1

Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma

NCT00590603
COMPLETED

AREDS 2 Ancillary Spectral Domain Optical Coherence Tomography Study

NCT00734487
COMPLETED NA

β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients

NCT00672841
COMPLETED NA

Validation of Brain Oxygenation Monitor

NCT00815490
COMPLETED Phase 2

Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma

NCT00611325
COMPLETED

Correlation of Location of Abdominal Tenderness With Acute CT Abnormalities in Emergency Department Patients

NCT00673374
COMPLETED NA

Combining Objective and Subjective Sedation Assessment Tools

NCT00734409
COMPLETED NA

Tailored Case Management for Diabetes and Hypertension

NCT00978835
TERMINATED Phase 2

Aloxi for Prevention of Chemotherapy Induced Nausea and Vomiting in Malignant Glioma Patients Receiving Irinotecan With Bevacizumab

NCT00636805
COMPLETED Phase 2

Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan

NCT00613028
COMPLETED NA

Preventing Postpartum Return to Smoking

NCT00917943
COMPLETED NA

Adherence to Hydroxyurea in Children With Sickle Cell Anemia

NCT00672789
TERMINATED Phase 2

Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer

NCT00636441
COMPLETED

BraveNet Integrative Medicine Descriptive Study

NCT00636779
COMPLETED Phase 4

Rapid Sternal Closure System (TALON)

NCT00638014
COMPLETED Phase 3

Effectiveness of Ultrafiltration in Treating People With Acute Decompensated Heart Failure and Cardiorenal Syndrome (The CARRESS Study)

NCT00608491
COMPLETED Phase 1

Ph I SU011248 + Irinotecan in Treatment of Pts w MG

NCT00611728
TERMINATED Phase 3

Effectiveness of Surgical Mitral Valve Repair Versus Medical Treatment for People With Significant Mitral Regurgitation and Non-ischemic Congestive Heart Failure

NCT00608140
TERMINATED Phase 1

Stereotactic Body Radiotherapy (SBRT) and Sorafenib in Patients With Metastatic, Recurrent, or Unresectable Renal Cell Cancer (RCC)

NCT00672178
COMPLETED Phase 3

Standard Percutaneous Nephrolithotomy Percutaneous Nephrolithotomy (PNL) Versus Tubeless PNL Versus Tubeless Stentless PNL

NCT01548196
COMPLETED NA

DAMES: Daughters And MothErS Against Breast Cancer

NCT00630591
COMPLETED NA

Community and Clinician Partnership for Prevention

NCT00577759
COMPLETED Phase 3

Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study)

NCT00577135
COMPLETED Phase 1

Ph I Dasatinib + Erlotinib in Recurrent MG

NCT00609999
COMPLETED Early Phase 1

Prevention and Treatment of Immersion Pulmonary Edema

NCT00815646
COMPLETED Phase 1

Study of Sorafenib/Cetuximab in Head and Neck Cancer

NCT00815295
TERMINATED Phase 2

NICardipine Neuroprotection in AortiC Surgery (NICNACS)

NCT00508118
TERMINATED Phase 4

A Trial Examining the Efficacy of Escitalopram Oxalate Upon Depressive Symptoms and Fatigue in HIV Seropositive Women

NCT01797380
TERMINATED Early Phase 1

An Open Label, Double-blind Discontinuation Study of Quetiapine Extended Release(XR)

NCT00606541
TERMINATED Phase 4

A Pilot Study of Daptomycin for Antimicrobial Prophylaxis

NCT00572260
COMPLETED NA

Inattention in Childhood Cancer Survivors

NCT00636337
COMPLETED NA

Attention Deficit Hyperactivity Disorder (ADHD) Smoking Cessation Study

NCT00736255
COMPLETED

Estimating Volume Using LiDCO

NCT00571441
← Previous Page 30 of 35 Next →

Phase Distribution

PhaseTrial count
Phase 1 136
Phase 2 175
Phase 3 41
Phase 4 134

Therapeutic Areas

Obesity 15
Breast Cancer 14
Hypertension 10
Anxiety 10
Cardiovascular Diseases 10
Heart Failure 9
Cancer 9
Pediatric Obesity 8
Pain 8
Depression 8

What is open in the Duke University pipeline

187 recruiting of 1,725 indexed (11% open); 1,244 completed (72%).

Phase mix: 175 late (III/IV) vs 311 early (I/II) (early-phase heavy).

Top condition: Obesity (15 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Duke University: open-pipeline peers nationwide

Peers matched on 1,725 registered trials and 11% open enrollment, not the therapeutic-area sidebar.

Duke University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,5002,000 5%10%15%20% Total trials Recruiting share Duke UniversityUniversity of California, San FranciscoStanford UniversityVA Office of Research and DevelopmentPfizerCarnegie Mellon UniversityCAMC Health SystemUConn HealthHartford Hospital
Duke University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Duke University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,725 trials (± recruiting share)

Sponsors near 11% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Duke University page

1,725 registered trials is a research-attention snapshot, not an endorsement of Duke University or any single study.

  • 187 of Duke University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Obesity is the condition Duke University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Duke University pipeline card: 1,725 registered trials from official public datasets.Report a data error.